New combo attack on deadly thyroid cancer shows early promise
NCT ID NCT03975231
First seen Nov 11, 2025 · Last updated May 21, 2026 · Updated 23 times
Summary
This early-stage trial tests whether adding two targeted drugs (dabrafenib and trametinib) to standard radiation therapy can better treat a rare and fast-growing thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF mutation). The study involves 6 people and aims to find the safest dose of the drug combination when given with radiation. The goal is to shrink or kill more tumor cells than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Univ of Texas-M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.